This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content

VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:

Sign In or Create an Account

or View more offersArticle content

  • Wells Fargo Healthcare Conference, Boston, MA
    Fireside Chat: Wednesday, September 9, 11:00–11:30 am ET

Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Details about the presentation, including webcast information, can be found on the Investors section of Xenon’s website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change.

Article contentArticle content

About Xenon Pharmaceuticals Inc. 

Article content

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.

Article content

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner. 

Article content

Contacts: 

Article content

For Investors:  
Tucker Kelly  
Chief Financial Officer  
[email protected]  

Article content

For Media:  
Colleen Alabiso  
Senior Vice President, Corporate Affairs  
[email protected]  

Article contentArticle content
Article contentArticle contentArticle contentArticle contentThis advertisement has not loaded yet.Trending


  1. Posthaste: Markets predict three Bank of Canada rates hikes are coming and some economists agree

    News


  2. Charles St-Arnaud: Trump’s Venezuelan oil deal is further proof Canada needs to diversify — now

    Oil & Gas

  3. Story continues belowThis advertisement has not loaded yet, but your article continues below.

  4. Which states stand to suffer most in escalated U.S.-Canada trade war?

    Economy


  5. Bank of Canada’s new $20 bill features new security features and Canadian, Indigenous motifs

    News


  6. Smaller Toronto condos losing value twice as fast: report

    Real Estate